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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.023Sphingosine-1-phosphate (S1P) is produced by sphingosine kinase 1 and is implicated in tumor growth,
although the mechanisms remain incompletely understood. Pancreatic stellate cells (PSCs) reside within the
tumor microenvironment and may regulate tumor progression. We hypothesized that S1P activates PSCs to
release paracrine factors, which, in turn, increase cancer cell invasion and growth. We used a combination of
human tissue, in vitro, and in vivo studies to mechanistically evaluate this concept. Sphingosine kinase 1
was overexpressed in human pancreatic tissue, especially within tumor cells. S1P activated PSCs in vitro and
conditioned medium from S1P-stimulated PSCs, increased pancreatic cancer cell migration, and invasion,
which was dependent on S1P2, ABL1 (alias c-Abl) kinase, and matrix metalloproteinase-9. In vivo studies
showed that pancreatic cancer cells co-implanted with S1P2 receptor knockdown PSCs led to less cancer
growth and metastasis in s.c. and orthotopic pancreatic cancer models compared with control PSCs.
Pancreatic cancer cellederived S1P activates PSCs to release paracrine factors, including matrix
metalloproteinase-9, which reciprocally promotes tumor cell migration and invasion in vitro and cancer
growth in vivo. (Am J Pathol 2014, 184: 2791e2802; http://dx.doi.org/10.1016/j.ajpath.2014.06.023)Supported by NIH grants DK59615 (V.S.), AA021171 (V.S.), and K12
CA90628 (B.J.) and Clinical Core of the Mayo Clinic Center for Cell
Signaling in Gastroenterology grant P30DK084567 (V.S.).
Disclosures: None declared.Sphingosine-1-phosphate (S1P) is a lipid-signaling molecule
that governs growth, survival, and migration of epithelial
cells.1,2 S1P is converted from sphingosine through a reaction
that is catalyzed by sphingosine kinase (SK), which exists in
two isoforms: SK1 and SK2. S1P is produced intracellularly
and then exported out, where it binds its receptors S1P1 and
S1P2, which couple to distinct G proteins and signaling
pathways.2 Accumulating evidence indicates that excessive
S1P signaling correlates with cancer phenotype, including up-
regulation of S1P and/or SK1 in several cancer types3 and
correlation of the levels of these molecules with patient
prognosis. However, the mechanistic relationship of the S1P
pathway with cancer growth remains incompletely developed.
Additional lines of evidence link S1P signaling with
ﬁbrosis. Indeed, S1P induces extracellular matrix synthesis
and proﬁbrotic marker gene expression. Mice genetically
deﬁcient in S1P2 are resistant to liver ﬁbrosis.4,5 These ob-
servations are relevant to pancreatic cancer, in which the tumor
microenvironment is characterized by dense ﬁbrotic stromastigative Pathology.
.owing to enhanced matrix production by activated pancreatic
stellate cells (PSCs).6e8 Indeed, the activation phenotype of
PSCs, characterized by increased proliferation, migration,
synthesis of matrix proteins, and secretion of growth factors
and cytokines, is thought to occur in response to tumor
cellederived cues and, in turn, contribute to tumor growth
through multiple postulated mechanisms.6,9,10 This led us to
explore whether S1P may mediate reciprocal interactions be-
tween tumor cells and PSCs that could sanction tumor growth.
Herein, we found that SK1 is up-regulated in pancreatic
cancer. S1P activates PSCs to produce matrix
metalloproteinase-9 (MMP-9) through an S1P2-, c-Able, and
NF-kBedependent pathway. In turn, PSC-derived MMP-9
stimulates pancreatic cancer cell migration and invasion. Both
Bi et als.c. and orthotopic pancreatic cancer models indicate that this
molecular pathway regulates tumor growth in vivo. These
studies highlight the importance of S1P signaling as a mech-
anism that links the tumor with its microenvironment to ach-
ieve tumor growth in pancreas.
Materials and Methods
Cell Culture and Transfection
Immortalized mouse PSCs,11 immortalized human PSCs,12
human pancreatic cancer cell lines PANC1,13 ASPC1,14 and
L3.6 cells15 were obtained from Dr. Debabrata Mukhopadhyay
and Dr. Raul A. Urrutia (Mayo Clinic, Rochester, MN).
c-Abl//Arg/ MEF cells were kindly provided by Dr.
Edward B. Leof (Mayo Clinic).16 Cells were cultured under
standard conditions in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum and antibiotics
(penicillin and streptomycin) in a 5% CO2-humidiﬁed atmo-
sphere. For transfection experiments, cells were seeded onto
6-well plates, and cultured for 24 hours to be 50% to 60%
conﬂuent on the day of transfection. siRNA transfection was
performed using Oligofectamine (Life Technologies, Grand
Island, NY, USA) according to the manufacturer’s protocol.
Knockdown efﬁciency was determined by real-time PCR
for S1P1, S1P2, and c-Abl mRNA or by Western blot analysis.
Sequences of siRNAs (sense) used in this study are as
follows: non-target siRNA, 50-ATGTGCCTATGACTGTT-
CGTT-30; S1P1 siRNA, 50-AAGCAGAAGAGAATATA-
GTGC-30; S1P2 siRNA, 50-CAGGAACACUACAAUUACA-
30; c-Abl siRNA, 50-GAAGGGAGGGUGUACCAUU-30; and
MMP-9 siRNA, 50-TGGACGATGCCTGCAACGTG-30.
Lentiviral vectors encodingS1P2 shRNAswere purchased from
Sigma-Aldrich (St. Louis, MO) (NM_003870.2-6211s1c1,
NM_003870.2-3950s1c1, and NM_003870.2-569s1c1). Len-
tiviruses were generated by Vira Power Lentiviral Expression
Systems (Life Technologies).
Boyden Chamber Assay and Transwell Assay
Migration assays were conducted using a modiﬁed Boyden
chamber assay with 8-mm porosity polyvinylpyrrolidone-free
polycarbonate ﬁlters precoated with 10 mg/mL type I
collagen. Brieﬂy, 1 104 PSCs or PANC1 cells were seeded
in 50-mL culture medium in the upper chambers with 50-mL
serum-free Dulbecco’s modiﬁed Eagle’s medium containing
vehicle or S1P, or conditioned medium, in the lower cham-
bers. After 5 hours of incubation, cells on the upper surface of
the inserts were removed using a cotton swab, and those that
had migrated through the ﬁlter were ﬁxed, permeabilized,
and stained with DAPI. Transwell assays were done in 12-
well plates with Transwell inserts (Corning, Corning, NY)
equipped with 5-mm pores (Corning) coated with 20 mg/mL
Matrigel (BD Biosciences, San Jose, CA) at 37C overnight.
Cells (1 to 2 105) were seeded in the upper well and serum-
free medium with vehicle or S1P or conditioned medium, as2792indicated, in the lower well. After completion, membranes
were removed, wiped on the side facing the upper well, and
stained with crystal violet. At least six representative images
of each well were taken, and cell numbers were counted using
ImageJ software version 1.47 (NIH, Bethesda, MD). The
experiments were performed in triplicate.
RNA Preparation, PCR Array, and qPCR
Total RNA was extracted using the TRIzol method (Life
Technologies) and cleaned with the RNeasy Mini kit (Qiagen,
Crawley, UK), according to the manufacturer’s instructions.
RNA was reverse transcribed with SuperScript II Reverse
Transcriptase (Life Technologies) using OligoDT primers.
cDNA was quantiﬁed using a spectrophotometer (Beckman
Coulter, Brea, CA). RT2 Proﬁler PCR Array (Qiagen) was
performed per manufacturer’s instruction. Reverse tran-
scriptionequantitative real-time PCR (RT-qPCR) was per-
formed (model 7500 Realtime PCR System; Applied
Biosystems, Foster City, CA) to quantify the steady-state
concentration of RNA using a Bio-Rad iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA). Primers used for this study
are as given below. Human primers were as follows: MMP-9,
50-CGACGTCTTCCAGTACCGA-30 (forward) and 50-CTC-
AGGGCACTGCAGGAT-30 (reverse); SK1, 50-AATTTCA-
AATATTGAACAGCTCGGAA-30 (forward) and 50-TTT-
ATAATGTTTGACATGGTCTCCTTT-30 (reverse); smooth
muscle actin (SMA), 50-GGAGATCACGGCCCTAGCAC-30
(forward) and 50-AGGCCCGGCTTCATCGTAT-30 (re-
verse); colony-stimulating factor (CSF)1, 50-GCTGTTGT-
TGGTCTGTCTC-30 (forward) and 50-CATGCTCTTCAT-
AATCCTTG-30 (reverse); and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), 50-CCAGGGCTGCTTTTAA-
CTCT-30 (forward) and 50-GGACTCCACGACGTACT-
CA-30 (reverse). Mouse primers were as follows: CSF1r,
50-CCACCATCCACTTGTATGTCAAAGAT-30 (forward)
and 50-CTCAACCACTGTCACCTCCTGT-30 (reverse);
and GAPDH, 50-ACCACAGTCCATGCCATCAC-30 (for-
ward) and 50-CACCACCCTGTTGCTGTAGCC-30 (reverse).
The reaction contained 10 ng cDNA and 0.5 mm primers.
The relative expression (fold of GAPDH) of each gene was
calculated using the DCT method.
Construction of Luciferase Reporter Plasmid and
Luciferase Activity Assay
Wild-type MMP9 promoter luciferase reporter, and MMP9
promoter luciferase reporters with a point mutation in anNF-kB
binding site were generous gifts from Dr. Hiroshi Sato (Kana-
zawa University, Kanazawa, Japan).17 The constructs were
cloned into a pWPXLd vector and then transfected 293T cells to
generate lentivirus. PSCs were transformed with the lentivirus
expressing wild-type MMP9 promoter luciferase reporter or
reporters harboring anNF-kBbinding sitemutation for 72 hours
and then split into 96-well plates before the cells were starved
and then stimulated with agonists for 6 hours, as indicated.ajp.amjpathol.org - The American Journal of Pathology
S1P and Stellate CellsLuciferase activities weremeasured using a Luciferase Reporter
Assay System (Promega, Madison, WI) with a TD-20/20
luminometer (Tuner Designs, Sunnyvale, CA), according to
the manufacturer’s instructions. Adenovirus expressing NF-kB
activity luciferase reporter was described previously.18
Western Blot Analysis and Zymography
Cells were washed with ice-cold phosphate-buffered saline
(PBS) and then lysed in radioimmunoprecipitation assay buffer:
10 mmol/L Tris-Cl (pH 8.0), 1 mmol/L EDTA, 0.5 mmol/L
EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1%
SDS, and 140 mmol/L NaCl. Protein concentration in lysates
was used to normalize loading of gels. Cell extracts and condi-
tioned medium were diluted fourfold in lysis buffer, reduced
with 5% b-mercaptoethanol, and then fractionated by SDS-
PAGE and analyzed by Western blot analysis. Detection was
performed using enhanced chemiluminescence. MMP-9 met-
alloproteinase activity in conditionedmediumwas evaluated by
zymography, as described.19 Brieﬂy,mediumwas collected and
centrifuged at 270  g for 3 minutes to remove cellular debris.
Polyacrylamide gels (7.5%) containing 2 mg/mL gelatin were
subjected to electrophoresis under nonreducing conditions.
After electrophoresis, SDS was removed by washing in 2.5%
TritonX-100, andgelswere incubated at 37Cfor 18hours in50
mmol/LTris-HCl, pH8.0, 50mmol/LNaCl, 10mmol/LCa2Cl,
and 0.05% Triton X-100. Gels were then stained in 0.2%
Coomassie Brilliant Blue. Gelatinase activity was detected as
clear bands on a dark background. Densitometric analysis of
bands was performed using ImageJ software.
Tissue Immunoﬂuorescence and
Immunohistochemistry
Specimens containing pancreatic cancer or normal pancreatic
tissue samples were obtained from Mayo Clinic Gastroen-
terology tissue bank and Mayo Clinic Pancreas Spore. The
protocol was approved by the Mayo Clinic Institutional Re-
view Board. Tissue frozen sections were subjected to double
immunoﬂuorescence for cytokeratin 19 and SK1. Images
were acquired by an LSM 5 Pascal Laser Scanning Micro-
scope (Zeiss, Thornwood, NY). Animal tissues from ortho-
topic and s.c. pancreatic cancer models were embedded in
optimum cutting temperature, and tissue sections were ﬁxed
with 4% paraformaldehyde and blocked with 5% bovine
serum albumin, incubated with indicated primary antibodies
at 4C overnight and with ﬂuoro-conjugated secondary
antibody for 1 hour. TOTO3 was incubated with cells for 30
minutes before the slides were washed and mounted onto a
glass slide. Images were acquired and processed using Zeiss
LSM image programs. Ten random parafﬁn sections of liver
were immunostained for STEM21 (StemCells, Inc., Newark,
CA) to identify tumor micrometastasis. The number of ani-
mals with micrometastasis detected by microscopy under a
high-power ﬁeld was recorded for each group, and the per-
centage of positive animals was reported.The American Journal of Pathology - ajp.amjpathol.orgSubcutaneous and Orthotopic Pancreatic Cancer
Models
Eight-week-old male nude mice were used to generate s.c. and
orthotopic pancreatic cancer models, as described earlier.10,20
Brieﬂy, human pancreatic cancer cells (0.5  106 L3.6 or
0.25  106 ASPC1) (50 mL in PBS) were mixed with human
PSCs (1:1), transformed with non-target control siRNA
(NTsh) or speciﬁc shRNA targeting S1P2 (S1P2sh) for 72
hours (50 mL in PBS), and were co-injected into the lower
ﬂank of nude mice for the s.c. model or pancreas tail for the
orthotopic model using a 0.5-mL syringe and a 27-gauge
needle (12 mice were in each group). To facilitate the obser-
vation of tumor growth in vivo, ASPC1 and L3.6 cells were
labeled with luciferase, and PSCs were stably transfected with
green ﬂuorescent protein. For the s.c. pancreatic cancer model,
tumor diameters were measured by a caliper every 3 days after
implantation and tumor volume was calculated by the
following formula: tumor volumeZwidth2  length=2.
For the orthotopic model, tumor size was monitored in vivo
after administration of 150 mL of 15 mg/mL D-luciferin to the
mice at days 6 and 12 after tumor implantation and in vivo
xenogen imaging was performed using a Xenogen IVIS 200
machine (Caliper Life Sciences, Waltham, MA). Mice were
sacriﬁced 14 or 28 days after co-implantation. Tumors were
isolated and weighted. Tissue sections were subjected to RT-
qPCR, immunoﬂuorescence (IF), immunohistochemistry,
and in situ zymography. Each group consisted of 5 to 10 mice.
In Situ Zymography
In situ zymography was performed, as previously described,21
with modiﬁcation. Frozen section tissue slides were overlaid
with 1 mg/mL DQ collagen (DQ Collagen, type I; Bovine
Skin; Life Technologies) in 1% low melting agarose. Slides
were kept in 4C for 30 minutes to allow agarose to solidify
and then incubated at 37C for 1 hour. Under confocal ﬂuo-
rescent examination, collagenolytic/gelatinolytic activity was
detected as bright greeneappearing zones.
Statistical Analysis
Results are expressed as means  SE. Signiﬁcance was
established using the Student’s t-test and analysis of variance,
when appropriate. P < 0.05 was considered signiﬁcant.
Results
Human Pancreatic Cancer Cells Overexpress SK1 to
Generate S1P, Which, in Turn, Activates PSCs
Accumulating evidence supports a role for the S1P pathway in
cancer; levels of SK1 mRNA and/or protein are increased
in tumors of the stomach,22 lung,23 brain astrocytoma,24 colon,25
non-Hodgkin lymphoma,26 and breast.27 Furthermore,
increased SK1 expression correlated with increased tumor2793
Bi et algrade and reduced patient survival.28 However, the links be-
tween S1P signaling and pancreatic cancer remain poorly un-
derstood.3 To identify the cellular source of SK1 from
pancreatic cancer, ﬁrst, we used IF microscopy to show that,
although SK1 expression in normal human pancreatic ducts
was minimal (Figure 1A), there was high expression of SK1 in
cytokeratin 19epositive pancreatic cancer cells (Figure 1A).
On the basis of this observation, we examined SK1 mRNA
levels in pancreatic cancer tissues. RT-qPCR showed increased
SK1 mRNA levels in pancreatic cancer tissue compared with
control pancreas (Figure 1B).
Reciprocal interactions between stellate cells and cancer
cells are critical for pancreatic cancer progression and metas-
tasis. To examine if pancreatic cancer cellederived S1P can
activate PSCs, we examined effects of S1P on PSCs. Indeed,
S1P stimulation increased extracellular signal-regulated kinase2794and AKT phosphorylation in both human and mouse
immortalized PSCs, which peaked at 5 to 10 minutes and
persisted for at least 60 minutes (Figure 1C and data not
shown). Furthermore, S1P mobilized actin re-organization,
stimulated cell proliferation, and promoted proﬁbrotic gene
expression, including ﬁbronectin and collagen 1a (Figure 1,
DeF). Thus, these data indicate that S1P can activate PSCs.
S1P-Activated PSCs Stimulate PANC1 Cell Migration
and Invasion
After we showed that pancreatic cancer cells can activate PSCs
through effects of S1P, we next explored if S1P-activated PSCs
could reciprocally regulate tumor cell behavior and growth
using conditioned media experiments. We applied conditioned
media collected from S1P-treated PSCs onto the human
pancreatic cancer cell line, PANC1, and assessed cancer cell
migration and invasion. Conditioned media from S1P-
stimulated PSCs signiﬁcantly increased PANC1 cell migra-
tion and invasion (Figure 2A) by 6.7- and 5.8-fold compared
with vehicle-treated PSC-conditioned media using Boyden and
Transwell assays, respectively. Similarly, conditioned medium
from S1P-treated PSCs also stimulated cell migration in another
human pancreatic cancer cell line L3.6 by 3.8-fold compared
with vehicle-treated conditioned medium (Figure 2B).
S1P Transcriptionally Activates MMP9 in PSCs
We next investigated the molecular mechanisms of how S1P-
stimulated PSCs affect cancer cells. As an initial step to identify
factors secreted from PSCs that may activate the tumor micro-
environment and tumor growth, we treated PSCs with S1P and
performed a screening with an angiogenesis pathwayespeciﬁc
PCR array. Among 84 factors that were included in the PCRFigure 1 Sphingosine kinase 1 (SK1) is overexpressed in human pancre-
atic cancer cells. A: Immunoﬂuorescence of cytokeratin 19 (red) and SK1
(green) on normal human pancreas and pancreatic cancer tissue frozen sec-
tions. Tumor cells are positive for both cytokeratin and SK1. mRNA was
extracted from normal human pancreatic tissue and human pancreatic cancer
tissues and then subjected to real-time PCR for SK1. Relative mRNA expression
level of human pancreatic cancer tissue was compared with normal pancreas.
B: Data shown represent human pancreatic cancer SK1 mRNA fold changes
compared with normal pancreas tissue (nZ 5). C: Sphingosine 1-phosphate
(S1P) induces human PSC Erk/AKT activation. Overnight starved pancreatic
stellate cells (PSCs) were treated with vehicle or 0.5 mm S1P for the indicated
time before proteins were subjected to Western blot analysis. D: S1P increases
actin stress ﬁber and focal adhesion formation. PSCs were plated on poly-D-
lysineecoated coverslips and starved overnight before 0.5 mm S1P treatment
for 15 minutes. Actin stress ﬁbers were stained with rhodamine phalloidin
(red), and focal adhesions were stained with vinculin conjugated with sec-
ondary Alex 488 Fluro antibody (green; Life Technologies). E: S1P increases
PSC proliferation. PSCs were plated in 96-well plates and starved overnight
before being treated with vehicle or S1P at the indicated concentration. An
MTS proliferation assay was performed 48 hours later (nZ 4). F: S1P stimu-
lates ﬁbronectin (FN) and collagen 1a mRNA production. Serum-starved PSCs
were subjected to vehicle or S1P treatment, and mRNA was extracted for
RT-qPCR. Data shown were fold changes compared with vehicle treatment
(nZ 3). *P < 0.05. Ctrl, control.
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S1P and Stellate Cellsarray, 46 were up-regulated by more than twofold
(SupplementalTableS1).We further focusedonMMP-9,which
was increased by 4.2-fold, on the basis of the knowledge that it is
critical for cancer cell invasion and metastasis.29,30 The array
result forMMP-9was conﬁrmedbyRT-qPCRshowingS1Pup-
regulation ofMMP-9mRNA levels by fourfold in human PSCsThe American Journal of Pathology - ajp.amjpathol.org(Figure 2C) and 3.2-fold in mouse PSCs (Figure 2D). MMP-9
zymographic activity also increased in a dose-dependent
manner that peaked at 2.6-fold with 1 mm of S1P (Figure 2E).
The lack of further increase of MMP-9 by high S1P concen-
trations beyond 5 mm is likely due to off-target effects on other
processes, such as cell apoptosis and proliferation.31 In PSCsFigure 2 Sphingosine 1-phosphate (S1P)-
activated pancreatic stellate cells (PSCs) stimulate
PANC1 cell migration and invasion. PSCs were
treated with vehicle (bovine serum albumin) or
0.5 mm S1P for 4 hours before being washed, and
fresh serum-free medium was added. Conditioned
medium was collected 48 hours later. A: Repre-
sentative micrographs of PANC1 cell migration
after 3-hour treatment with vehicle or S1P-treated
PSC-conditioned medium using Boyden chamber
assay; representative micrographs of PANC1 cell
invasion 24 hours after conditioned medium was
collected from vehicle-treated PSCs or S1P-treated
PSCs using Transwell assay. Quantitative data of
Boyden chamber and Transwell assay. B: Repre-
sentative micrographs of L3.6 cell migration after
3-hour treatment with vehicle or S1P-treated PSC-
conditioned medium using Boyden chamber assay.
Quantitative data of Boyden chamber. C and D:
S1P up-regulates MMP-9 mRNA. mRNA was
extracted from human (C) or mouse (D) PSCs,
stimulated with vehicle or 0.5 mm S1P for 2 hours
and subjected to RT-qPCR for MMP-9. E: S1P up-
regulates MMP-9 zymographic activity. PSCs were
treated with vehicle or the indicated concentra-
tion of S1P for 2 hours. Medium was collected 24
hours later for gelatin zymography. MMP-9 stan-
dards were used to identify the correct MMP-9
band. E: Representative image and quantitation
of zymography. F: S1P up-regulates MMP9 pro-
moter activity. PSCs were infected with lentivirus
expressing wild-type MMP-9 receptor luciferase
reporter and then subjected to vehicle or S1P
treatment for 6 hours. F: Luciferase activity fold
increase. G: S1P does not up-regulate MMP-9
mRNA levels in human pancreatic cancer cell lines
PANC1 and ASPC1. PANC1 and ASPC1 were stimu-
lated with vehicle or 0.5 mm S1P for 2 hours, and
mRNA was extracted and subjected to RT-qPCR for
MMP-9 (n Z 3). n Z 3 (CeE); n Z 4 (B and F).
*P < 0.05, **P < 0.01. BSA, bovine serum al-
bumin; HPF, high-power ﬁeld.
2795
Figure 3 Matrix metalloproteinase-9 (MMP-9) inhibition blocks PANC1 cell migration and invasion induced by sphingosine 1-phosphate (S1P)estimulated
pancreatic stellate cells (PSCs). A: PANC1 cells were pretreated with MMP-9 inhibitor or vehicle for 30 minutes before conditioned medium from S1P-treated
PSCs was applied for Boyden chamber assay or Transwell assay. Quantitative data of Boyden chamber (B) and Transwell (C) assays. PSCs were transfected with
NTsi or MMP-9si and then treated with S1P. D: Conditioned medium from S1P-treated PSCs was applied to PANC1 cells for Transwell assay; quantiﬁcation of
Transwell assay. n Z 4 (B); n Z 3 (C and D). *P < 0.05, **P < 0.01. HPF, high-power ﬁeld.
Bi et altransduced with a lentivirus construct expressing a luciferase
reporter driven by a wild-typeMMP9 promoter, S1P increased
MMP9 promoter activity by 2.5-fold (Figure 2F). These data
indicate that S1P stimulates MMP9 gene expression and
active MMP-9 protein production in PSCs. In contrast, S1P
failed to induce MMP-9 expression in pancreatic cancer
cells, PANC1, and ASPC1 (Figure 2G).
PSC-Derived MMP-9 Promotes Tumor Cell Migration and
Invasion
Up-regulation of MMP-9 is associated with increased cell
migration, invasion, and cancer metastasis. We next exam-
ined whether MMP-9 contributes to the enhanced migratory
and invasive properties of the PANC1 cells, conferred by
S1P-stimulated PSC-conditioned media. Therefore, we
pretreated PANC1 cells with an MMP-9 inhibitor before
exposing the cells to the conditioned media collected from
S1P-treated PSCs. PANC1 cells pretreated with MMP-9
inhibitor, compared with vehicle pretreated PANC1 cells,
showed less migration and invasion on stimulation with
conditioned media from S1P-treated PSCs (Figure 3, AeC).
In addition, conditioned medium from S1P-treated PSCs
with MMP-9 knockdown with MMP-9 siRNA also
demonstrated decreased PANC1 cell invasion compared
with control (Figure 3D). The data suggested that MMP-9
released from PSCs on S1P treatment mediated the stimu-
latory effect of PSCs on pancreatic cancer cell migration and
invasion.
S1P2 Receptor Is Required for S1P-Induced MMP-9
Production in PSCs
After we conﬁrmed that MMP-9 was up-regulated by S1P
and was required for PSC-conditioned media stimulation of
tumor cell migration, we next investigated the mechanism of
MMP-9 transcriptional regulation by S1P at different levels
in PSCs from receptor to nucleus. We ﬁrst determined which2796S1P receptor was responsible for MMP-9 production on S1P
treatment. We used two distinct siRNAs and/or shRNAs
speciﬁcally targeting S1P1 or S1P2 gene transcripts as well
as pharmacological inhibitors selectively targeting S1P1 or
S1P2, respectively. siRNA transfection effectively decreased
levels of S1P1 and S1P2 mRNA by 60% to 80%, as assessed
by RT-qPCR (Figure 4A). S1P-induced up-regulation of
MMP-9 luciferase reporter was markedly inhibited by
siRNA targeting S1P2, but not S1P1 (Figure 4A). In addi-
tion, S1P-inducedMMP-9 luciferase activity was blocked by
pretreatment of PSCs with JTE-013, an antagonist of S1P2,
but not by W146, an antagonist of S1P1 (Figure 4B). These
data indicate that S1P2 receptor mediates S1P-induced
MMP-9 up-regulation. To examine if S1P2 on PSCs is
responsible for the stimulatory effect of S1P-conditioned
media on PANC1 cell migration and invasion, we incu-
bated conditioned media from S1P2-knockdown PSCs
(S1P2sh PSCs) and control PSCs (NTsh PSCs) with tumor
cells. RT-qPCR showed that S1P2sh decreased the S1P2
level by 60% compared with NTsh (Figure 4C). Conditioned
media from S1P2sh PSCs stimulated less tumor cell migra-
tion and invasion compared with control PSCs (Figure 4,
DeF). These data indicate that S1P2 on PSC mediates the
stimulating effect of S1P-treated PSC-conditioned media on
tumor cell migration and invasion.
c-Abl Is Phosphorylated by S1P and Is Critical for
MMP-9 Production
In light of the in vitro and in vivo data showing that S1P2-
mediated MMP-9 from PSCs is critical for pancreatic cancer
migration, invasion, and growth, we next investigated the
mechanisms by which S1P induces MMP-9 production in
PSCs. c-Abl is a nonreceptor tyrosine kinase that engages in
a variety of intracellular processes, including MMP activ-
ities.32 We, therefore, hypothesized that c-Abl may be a
candidate protein that could mediate S1P stimulation of
MMP-9 production in PSCs. We ﬁrst tested if S1Pajp.amjpathol.org - The American Journal of Pathology
Figure 4 Sphingosine 1-phosphate (S1P)2 receptor mediates S1P-induced matrix metalloproteinase-9 (MMP-9) production in PSC cells. A: S1P2 knockdown
decreases MMP-9 luciferase reporter activity. PSCs expressing wild-type MMP-9 luciferase reporter were transfected with S1P1si, S1P2si, or NTsi for 72 hours,
and luciferase assay was performed 6 hours after S1P treatment. RT-qPCR shows that S1P1 and S1P2 are effectively knocked down by respective siRNA.
Knockdown of S1P2, but not S1P1, decreases MMP-9 luciferase reporter activity. B: Inhibition of S1P2 decreases MMP-9 luciferase reporter activity. PSCs stably
expressing wild-type MMP-9 luciferase reporter activity were pretreated with W146 or JTE for 30 minutes before S1P stimulation for 6 hours. CeF: S1P2
receptor is involved in PANC1 cell migration induced by the conditioned media from S1P-stimulated PSCs. PSCs were transfected with lentivirus expressing
NTshRNA or S1P2shRNA for 24 hours. Cells were starved overnight and treated with 0.5 mm S1P for 4 hours before being washed, and fresh serum-free medium
was added. Conditioned medium was collected 48 hours later and applied on PANC1 cells for Boyden chamber assay and Transwell assay. C: RT-qPCR shows
S1P2 is effectively knocked down by S1P2shRNA. D: Representative micrographs of PANC1 cell migration after conditioned medium was collected from S1P-
treated NTsh PSCs or S1P-treated S1P2sh PSCs for 3 hours using Boyden chamber assay. Representative micrographs of PANC1 cell invasion in response to
conditioned medium collected from S1P-treated NTshPSCs or S1P-treated S1P2sh PSCs using Transwell assay. Quantiﬁcation data of Boyden chamber (E) and
Transwell (F) assays. n Z 4 (A and B); n Z 3 (C, E, and F). *P < 0.05, **P < 0.01. BSA, bovine serum albumin; HPF, high-power ﬁeld.
S1P and Stellate Cellsphosphorylates c-Abl at speciﬁc tyrosine residues that
regulate its activity.32e34 Y245 of c-Abl showed minimal
basal phosphorylation, which increased 5 minutes after S1P
stimulation (Figure 5, A and B). In addition, S1P increased
phosphorylation of CrkII, a c-Abl substrate, at tyrosine 221
(Figure 5, A and C). Phosphorylation at Y89 and Y412 was
also increased 5 minutes after S1P stimulation (Figure 5D).
We next investigated a causative role of c-Abl in S1P-
induced MMP-9 production in PSCs. We used a c-Abl//
Arg/ MEF cell line derived from c-Abl and Arg double-
knockout mice (due to the functional redundancy between
c-Abl and Arg). In contrast to wild-type MEF, the c-Abl//
Arg/ MEF cells failed to show increased MMP-9 activity
after S1P stimulation (Figure 5E). In addition, knockdown of
c-Abl with two distinct siRNAs diminished S1P-induced
MMP9 promoter luciferase reporter activity (Figure 5F).
Thus, the data indicate that c-Abl is phosphorylated by S1P and
is required for S1P-induced MMP-9 production in PSCs.The American Journal of Pathology - ajp.amjpathol.orgNF-kB Activation Is Required for c-AbleMediated
S1P-Induced MMP9 Promoter Activation
To further delineate the mechanism of how c-Abl promotes
MMP-9 production, we determined if NF-kB was required
for the transcriptional activation of the MMP9 promoter
induced by S1P, because prior studies by us and others have
shown that functional NF-kB binding sites reside on the
MMP9 promoter.35,36 To this end, we used two strategies: an
adenovirus expressing an NF-kB activity luciferase reporter
driven by ﬁve copies of an NF-kB response element; and a
lentivirus expressing a human MMP-9 reporter luciferase
construct with a point mutation in the NF-kB binding site.
S1P signiﬁcantly increased NF-kB luciferase activity by 1.9-
fold in human PSCs but failed to increase MMP9 promoter
activity in the NF-kB mutant MMP-9 luciferase reporter
(data not shown). We further investigated if c-Abl could act
as the intermediary to activate NF-kB using the NF-kB2797
Figure 5 c-Abl phosphorylation is required for sphingosine 1-phosphate (S1P) activation of matrix metalloproteinase-9 (MMP-9) production. A: S1P
stimulates c-Abl phosphorylation at Y245. Human PSCs were treated with vehicle or 0.5 mm S1P or 10 pmol/L platelet-derived growth factor (PDGF) for the
indicated time and immunoblotted with Y245 phosphorylation-speciﬁc c-Abl, total c-Abl, phospho-Crk, and total Crk. Quantiﬁcation of the immunoblots of
phospho-speciﬁc c-Abl (B) and phospho-speciﬁc Crk (C). D: S1P stimulates c-Abl phosphorylation at Y87 and Y412. Human PSCs were treated with vehicle or
0.5 mm S1P for 5 minutes and immunoblotted with Y412 or Y89 phosphorylation c-Abl and total c-Abl. E: Zymography of MEF or MEF c-Abl//Arg/ cells on
treatment with S1P for 24 hours. F: Knockdown c-Abl with two different siRNAs blocks MMP-9 luciferase reporter activity induced by S1P. Human PSCs stably
expressing MMP-9 luciferase reporter were transfected with NTsi or c-Ablsi for 72 hours and then subjected to S1P or vehicle treatment for 6 hours before
luciferase assay was performed. G: NF-kB activation is required for S1P-induced MMP9 promoter activation. MEF or MEF c-Abl//Arg/ cells were infected
with an NF-kB luciferase reporter adenovirus for 16 hours and then subjected to vehicle or S1P treatment for 6 hours before luciferase assay. nZ 3 (B and C);
n Z 4 (F and G). *P < 0.05 versus BSA group (B and C) or versus NTsi (F) or versus BSA (G). BSA, bovine serum albumin.
Bi et alactivity luciferase reporter. In wild-type MEF cells, 0.1 mm
S1P signiﬁcantly stimulated NF-kB activity by 2.8-fold and
0.5 mm S1P by 4.8-fold (Figure 5G). In contrast to wild-type
MEF cells, S1P failed to increase NF-kB activity in the
c-Abl//Arg/ MEF cells (Figure 5G). These data indicate
that S1P stimulation of c-Abl can activate NF-kB and thereby
lead to MMP-9 production, thus providing mechanisms for
the previously mentioned functional and in vivo studies.
S1P2 Knockdown in PSCs Reduces Pancreatic Tumor
Growth in Vivo in s.c. and Orthotopic Pancreatic Cancer
Models
On the basis of these in vitro data, we hypothesized that
knockdown of S1P2 in PSCsmight modulate tumor cell growth
in vivo. Although PANC1 cells were used for in vitromigration
studies, these cells are not as aggressive as L3.6 cells for in vivo2798tumor studies on the basis of data in our model and corrobo-
rative reports from the literature.37 Therefore, L3.6 cells were
used for in vivo orthotopic and s.c. pancreatic cancer models.
We generated an s.c. pancreatic cancer model by co-implanting
0.5 106 L3.6 human pancreatic cancer cells and control NTsh
PSCs or S1P2sh PSCs, respectively, in a 1:1 ratio into 8-week-
old nude mice. It was previously shown that PSC co-
implantation augments tumor cell growth in this model.38e40
Tumor size was measured by a caliper every 3 days after im-
plantation, and tumor weight was measured at day 14. L3.6
cells alone showed the slowest growth curve and the lowest
tumor weight (Figure 6, A and B). Co-implantation of PSCs
with L3.6 cells signiﬁcantly promoted the tumor growth curve
and tumor weight (Figure 6, A and B). However, tumor growth
kinetics (Figure 6A) from S1P2sh PSCs and L3.6 co-
implantation were signiﬁcantly slower compared with NTsh
PSCs and L3.6 co-implantation (Figure 6, A and B), and theajp.amjpathol.org - The American Journal of Pathology
Figure 6 Knockdown of sphingosine 1-phosphate (S1P) 2 in pancreatic stellate cells (PSCs) reduces pancreatic tumor growth in the PSC pancreatic cancer
s.c. co-implantation model. L3.6 cells (0.5  106) were mixed 1:1 with NTsh PSCs or S1P2sh PSCs, respectively, and co-implanted into nude mice via s.c.
injection. Tumor nodules were measured by a caliper, and tumor volume was calculated. Tumor weight was measured after sacriﬁce. A: Tumor growth curves,
generated by monitoring mice carefully for 14 days (D), reveal that S1P2sh PSCs and L3.6 co-implantation have slower tumor growth compared with NTsh PSCs
and L3.6. B: Representative images of tumors, and average tumor weight. C: Less tumor angiogenesis is observed in tumor from S1P2sh PSC and L3.6 co-
implantation compared with control. Left panel: Tumor fresh-frozen sections were subjected to immunoﬂuorescence for von Willebrand factor (VWF;
green), SMA (red), or TOTO3 (blue). Right panel: Quantiﬁcation of tumor angiogenesis. D: RT-qPCR shows decreased CSF1 in S1P2sh PSCs versus NTsh PSCs.
RT-qPCR shows that tumors from S1P2sh PSC and L3.6 co-implantation have lower CSF1r compared with NTsh PSC and L3.6. E: Representative micrograph of IF
of F4/80 macrophage in tumor derived from co-implantation with NTsh PSCs or S1P2sh PSCs. F: In situ gelatinolytic activity colocalizes with SMA-positive cells.
Frozen tissue slides were subjected to in situ zymography with DQ-collagen (green). Tissue sections were subjected to IF for SMA (red) for colocalization
analysis. Representative micrograph is shown. G: MMP-9 mRNA is lower in tumors from S1P2sh PSC and L3.6 co-implantation compared with NTsh PSC and L3.6
co-implantation. Ratios of mRNA level to GAPDH are shown. *P < 0.05 versus S1P2sh and L3.6 (nZ 10; A); *P < 0.05 versus NTsh PSC and L3.6 (nZ 10; B);
*P < 0.05 versus NTsh group (n Z 10; C); *P < 0.05 (n Z 6; D); *P < 0.05 (n Z 10; G).
S1P and Stellate Cellsﬁnal tumor weight was reduced signiﬁcantly from 145 to 64mg
(Figure 6B). Staining for blood vessel endothelial cells with von
Willebrand factor (Figure 6C) or aquaporin (data not shown)
showed decreased angiogenesis in the tumor from S1P2sh
PSCs and L3.6 co-implantation compared with that from NTsh
PSCs and L3.6 co-implantation. Quantiﬁcation of angiogenesis
suggested>65% reduction in the tumor fromS1P2sh PSCs and
L3.6 co-implantation compared with control (Figure 7C). In
addition, knockdown of S1P2 in PSCs was associated withThe American Journal of Pathology - ajp.amjpathol.orgdecreased PSC CSF1 mRNA levels (Figure 6D), and the tu-
mors from S1P2sh PSCs and L3.6 co-implantation showed
decreased CSF1r mRNA levels (Figure 6D). Moreover, IF with
F4/80 for macrophages showed less macrophage inﬁltration in
the tumor from S1P2sh PSCs and L3.6 co-implantation
compared with NTsh PSCs and L3.6 co-implantation
(Figure 6E). These data indicated potentially important effects
of PSCs on other tumor microenvironment cells, including
endothelial cells and macrophages. In addition, tumors from2799
Figure 7 S1P2 knockdown in PSCs reduces pancreatic tumor growth and metastasis in an orthotopic pancreatic cancer model. Orthotopic pancreatic cancer
model was generated by injecting NTsh or S1P2sh PSCs with luciferase-labeled L3.6 (A and B) or ASPC1 (C and D) cells into the tail of pancreas of nude mice. A
and C: Bioluminescence of the cancer cells was quantitated by in vivo xenogene imaging at day 7 after implantation. B and D: Representative photographs of
pancreatic cancer from the orthotopic model. Average tumor weight from tumors co-implanted with S1P2sh PSCs is signiﬁcantly lower compared with that from
control PSCs. *P < 0.05, versus NTsh PSC þ L3.6 (n Z 6; B) or versus NTsh PSC þ ASPC (n Z 6; D).
Bi et alL3.6 cells alone had signiﬁcantly lower MMP-9 mRNA levels
compared with those of NTsh PSCs and L3.6 co-implantation.
In situ zymography suggested that protease activity was mainly
located in the stroma region with colocalization of SMA-
positive cells (Figure 6F). These data suggested that stroma
cells, rather than the tumor cells, are the main source of MMP
activity in tumors in vivo. Tumors from S1P2sh PSCs and L3.6
co-implantation showed decreased MMP-9 mRNA compared
with NTsh (Figure 6G), suggesting that S1P2 knockdown in
PSCs modulates MMP-9 production in the tumor microenvi-
ronment, which may, in turn, regulate cancer growth in vivo.
Pancreatic cancer is highly metastatic and, therefore, we
also sought to determine whether knockdown of S1P2 in
PSCsmight decrease tumor metastasis in vivo. To this end, we
used an orthotopic pancreatic cancer model in which PSCs
and cancer cells are directly injected into the tail of the
pancreas of nude mice, with subsequent metastasis to the
liver. This model also has the added advantage of better
recapitulating the pancreatic tumor microenvironment
compared with the s.c. model. Given the heterogeneity of
pancreatic cancer, we used two different pancreatic cancer cell
lines, AsPC1 and L3.6, in the orthotopic model. To facilitate
the observation of tumor growth in vivo, ASPC1 and L3.6
cells were labeled with luciferase, and PSCs were stably
transfected with green ﬂuorescent protein. In both ASPC1 and
L3.6 models, cancer cells co-implanted with S1P2sh PSCs
showed slower tumor growth and smaller tumor weight
(Figure 7, AeD). One animal in the orthotopic ASPC1 and
NTsh PSC co-implantation group developed obstructive
jaundice and visible nodules throughout the omentum.
Another two animals from the same group had visible nodules
on the surface of the liver. None of the animals from the
S1P2sh PSC and ASPC1 co-implantation group had jaundice
or visible nodules. Furthermore, by using a STEM21 antibody
that speciﬁcally recognized human cell but not murine cell
intracellular protein, we detected higher rates of microscopic2800metastasis to the liver in the orthotopic model with
co-implantation of cancer cells and NTsh PSCs [5 (83.3%) of
6] compared with S1P2sh PSCs [1 (16.7%) of 6].
Discussion
Pancreatic cancer remains one of the most devastating solid
tumors, despite intense research in this area. Strategies to target
the S1P pathway are emerging as a promising approach for
cancer therapy for multiple solid tumors. In the current study,
wemake several observations that expand our understanding of
the S1P signaling pathway, with associated therapeutic impli-
cations in the context of pancreatic cancer and tumor micro-
environment. We identify important paracrine interactions
between tumor cells and PSCs, whereby S1P activates PSCs to
generate MMP-9, which, in turn, stimulates pancreatic tumor
cell migration and invasion. Mechanistically, S1P stimulation
of MMP-9 production in PSCs occurs through a pathway
dependent on the nonreceptor tyrosine kinase c-Abl. Additional
in vivo and human studies provide evidence that the proposed
pathway is relevant in an integrative biological context. In total,
the data indicate that S1P promotes pancreatic cancer growth
through modifying tumor microenvironment, speciﬁcally
through the interactions of PSCswith cancer cells, and supports
the concept that targeting the PSC S1P axis may provide
therapeutic beneﬁt for pancreatic cancer.
Excessive activity of the S1P pathway has been detected in
various cancer types, including colon, breast, and lymphoma,
and, in turn, efforts to inhibit this pathway have been associated
with cancer regression.1,2 For example, the speciﬁc monoclonal
antibody sphingomab suppresses lung metastasis, and sonepci-
zumab (LPath, Inc., San Diego, CA), a humanized version of
sphingomab, has advanced to phase 2 clinical trials.41 However,
the underlyingmechanisms of how S1P promotes tumor growth
remain incompletely understood. Although previous studies
have shown salutary effects of S1P on cancer cellsajp.amjpathol.org - The American Journal of Pathology
S1P and Stellate Cellsthemselves,42,43 herein we focused on the role of S1P as a relay
switch that links cancer cells with their microenvironment,
especially PSCs. These cells transform into tumor-associated
myoﬁbroblasts during neoplastic growth, and increasing data
indicate that they contribute to tumor growth in important
ways.6,9,10 Indeed, we found that knockdown of S1P2 from
PSCs co-implanted with tumor cells diminishes tumor growth
not only through direct effects on tumor cells but also through
promoting dormancy of the tumor microenvironment, as evi-
denced by diminished angiogenesis andmacrophage inﬁltration.
Pancreatic cancers undergo dynamic remodeling, in part
through theMMP family of proteases.MMPs, includingMMP-
9, promote tumor progression through matrix degradation,
stimulation of angiogenesis, and ligation-mediated activation of
cancer cell signaling pathways.29,44 Indeed, increased expres-
sion of MMP-9 has been linked to increased cancer invasive-
ness in humans and in experimental models.45,46 However,
MMP inhibition in human trials has been disappointing.44,47,48
Our study suggests that stromal cells are a major source of
MMP activity in pancreatic cancer and inﬂuence tumor cell
biological characteristics. Thus, future clinical trials of speciﬁc
MMP-9 inhibitors could be modiﬁed to focus on stromal cell
MMPs and their paracrine effects on tumor cells.
c-Abl kinase is activated in several tumor types and con-
tributes to tumor cell motility, invasion, and metastasis49; it has
represented a successful therapeutic target for some cancers.50,51
The present study focuses on an alternative and indirect mech-
anism by which c-Abl in PSC promotes tumor invasion and
metastasis by stimulatingMMP-9 production that affects tumor
cell aggressiveness. Our studies indicate that the mechanism by
which c-AblmediatesMMP-9production ismediated, at least in
part, through activation of c-Abl with phosphorylation of c-Abl
atY412,Y245, andY89 inPSCs. In turn, c-Ablmay act through
NF-kB to mediate MMP-9 production. Indeed, NF-kB binding
sites have been identiﬁed on MMP9 promoter and evaluated
by us and others in prior studies.19,35,52 Recent studies have
also linked c-Abl with NF-kB through a noncanonical
mechanism.53 Although a clinical trial of the c-Abl inhibitor,
imatinib, failed to improve pancreatic cancer outcomes,54 the
present studies highlight several potential molecular targets
situated upstream and downstream from c-Abl, which may
warrant further attention.
Overall, our study shows that pancreatic cancers over-
express SK1 to produce S1P, which, in turn, acts on PSCs to
secrete multiple molecules, including MMP-9, to further
promote pancreatic cancer growth as a feed-forward loop.
Our data support the concept that targeting the S1P axis may
provide therapeutic beneﬁt for pancreatic cancer.Acknowledgments
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